Immunotherapy in prostate cancer: Challenges and opportunities

Immunotherapy

Volumn 8, Issue 1, 2016, Pages 69-77

  Noguchi, Masanori ^a,b   Koga, Noriko ^a   Moriya, Fukuko ^b   Itoh, Kyogo ^b  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

biomarker; cancer vaccine; immune checkpoint inhibitor; immunotherapy; prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CANCER VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; IPILIMUMAB; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE RESPONSE; MAINTENANCE CHEMOTHERAPY; MALE; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; VACCINATION; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANTIBODIES, MONOCLONAL; BIOMARKERS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84950262239     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.101     Document Type: Article

References (58)

1. Horwich A, Hugosson J, de Reijke T et al. Prostate cancer: RSMO Consensus Conference Guidelines 2012. Ann. Oncol. 24, 1141-1162 (2013).
2. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
3. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 376, 1147-1154 (2010).
4. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
5. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
6. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213-223 (2013).
7. Singh BH, Gulley JL. Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Thr. Adv. Vaccines. 2, 137-148 (2014).
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 144, 646-674 (2011).
9. Sfanos KS, Bruno RC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate. 69, 1694-1703 (2009).
10. Gabrilovich DI, Bronte V, Chen SH et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67, 425 (2007).
11. Genitsen WR, Sharma P. Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J. Clin. Immunol. 32, 25-35 (2012).
12. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J. Clin. Oncol. 29, 4828-4836 (2011).
13. Smith C, Chang MY, Parker KH et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2, 722-735 (2012).
14. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J. Immunol. Methods. 348, 9-17 (2009).
15. May KF Jr, Gulley JL, Drake CG, Dranoff G, Kantoff PW. Prostate cancer immunotherapy. Clin. Cancer Res. 17, 5233-5238 (2011).
16. Cha E, Small EJ. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer Cancer Med. 2, 243-252 (2013).
17. Baxevanis CN, Papamichail M, Perez S. Prostate cancer vaccines: the long road to clinical application. Cancer Immunol. Immunother. 64, 401-408 (2015).
18. Rini BI. Technology evaluation: APC-8015, Dendreon. Curr. Opin. Mol. Ther. 4, 76-79 (2002).
19. Small E, Fratesi P, Reese D et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894-3903 (2000).
20. Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6, 2175-2182 (2000).
21. Noguchi M, Yao A, Harada M et al. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 67, 933-942 (2007).
22. Schellhammer PF, Chodak G, Whitmore JB et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology. 81, 1297-1302 (2013).
23. Noguchi M, Kobayashi K, Suetsugu N et al. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate. 57, 80-92 (2003).
24. Noguchi M, Itoh K, Suekane S et al. Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci. 95, 77-84 (2004).
25. Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother. 42, 91-98 (2008).
26. Small EJ, Schellhammer PF, Higano CS et al. Placebocontrolled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094 (2006).
27. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 115, 3670-3679 (2009).
28. Fong L, Weinberg VK, Corman JM et al. Immune responses in prostate tumor tissue following neoadjuvant sipuleucel-T in patients with localized prostate cancer. J. Clin. Oncol. 30(Suppl. 5), Abstract 181 (2012).
29. Higano CS, Corman JM, Smith DC et al. Phase 1/2 doseescalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 113, 975-984 (2008).
30. Gerristen WR, Sharma P. Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J. Clin. Immunol. 32, 25-35 (2012).
31. Small E, Demknow T, Gerritsen W et al. A Phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs docetaxel plus prednisone in symptomatic, castration resistant prostate cancer (CRPC). Proc. Am. Soc. Clin. Oncol. Genitourinary Cancer Symposium(Abstract 7) (2009).
32. van den Ecrtwegh AJ, Versluis J, van den Berg HP et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a Phase I dose escalation trial. Lancet Oncol. 13, 509-517 (2012).
33. Madan RA, Arlen PM, Mohebtash M et al. Prostavac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs. 18, 1001-1011 (2009).
34. Arlen PM, Skarupa L, Pazdur M et al. Clinical safety of a viral vector-based prostate cancer vaccine strategy. J. Urol. 178, 1515-1520 (2007).
35. Eder JP, Kantoff PW, Roper K et al. A Phase I trial of a recombinant vaccina virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6, 1632-1638 (2000).
36. Marchall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-andboost vaccination protocol using recombinant vaccina virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 18, 3964-3973 (2000).
37. Gulley J, Chen AP, Dahut W et al. Phase I study of a vaccine using recombinant vaccina virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate. 53, 109-117 (2002).
38. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of Poxviralbased PSA-targeted immunotherapy in metastatic castrationresistant prostate cancer. J. Clin. Oncol. 28, 1099-1105 (2010).
39. Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol. Immunother. 62, 919-929 (2013).
40. Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K. A Phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate. 71, 470-479 (2011).
41. Noguchi M, Kakuma T, Uemura H et al. A randomized Phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol. Immunother. 59, 1001-1009 (2010).
42. Noguchi M, Moriya F, Suekane S et al. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate. 72, 834-845 (2012).
43. McNeel DG, Dunphy EJ, Davies JG et al. Safety and immunological efficacy of a DNA vaccine encoding prostate acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27, 4047-4054 (2009).
44. Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J. Immunother. 33, 639-647 (2010).
45. Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J. Exp. Med. 209, 201-209 (2012).
46. Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castrationresistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol. 24, 1813-1821 (2013).
47. Kwon ED, Drake CG, Scher HI et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castrationresistant prostate cancer that had progressed after docetaxel chemotherapy (CA 184-043): a multicentre, randomized, double-blind, Phase 3 trial. Lancet Oncol.15, 700-712 (2014).
48. Topalian SL, Hodi PS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
49. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
50. Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG. PD-1 or PD-L1 blockade restores antitumor efficacy following SSX2 epitope-modified DNA vaccine immunization. Cancer Immunol. Res. 3, 1-10 (2015).
51. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148-1159 (2008).
52. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol. Immunother. 60, 433-442 (2011).
53. Noguchi M, Mine T, Komatsu N et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol. Ther. 12, 1266-1279 (2011).
54. Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102, 1388-1397 (2010).
55. Amos SM, Duong CP, Westwood JA et al. Autoimmunity associated with immunotherapy of cancer. Blood. 118, 499-509 (2011).
56. López MN, Pereda C, Segal G et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J. Clin. Oncol. 27, 945-952 (2009).
57. Sheikh NA, Petrylak D, Kantoff PW et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized Phase 3 clinical trials in men with castrationresistant prostate cancer. Cancer Immunol. Immunother. 62, 137-147 (2013).
58. Santegoets SJ, Stam AG, Lougheed SM et al. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol. Immunother. 62, 245-256 (2013).